Actualización comercial
PLC de desarrollos de energía de mástil
(Incorporado en Inglaterra y Gales)
(Número de registro: 12886458)
LEI :213800HFVHGJ9YGO9F71
Compartir código en la LSE: MAST
ISIN: GB00BMBSCV12
('MED' o 'la Compañía')
Fecha: 26 de abril de 2024
Mast Energy Developments PLC ('MED' o 'la Compañía')
Actualización comercial
Mast Energy Developments PLC, propietario, desarrollador y operador de múltiples activos con sede en el Reino Unido en el mercado de energía flexible en rápido crecimiento, se complace en anunciar una actualización sobre cuestiones operativas comerciales.
Pyebridge
Further to the Company's previous RNS announcement dated 11 April 2024, MED has now received official confirmation that its Pyebridge 9MW flexible power generation asset ("Pyebridge") has passed its Satisfactory Performance Days ("SPD") requirements under its current existing T-1 Capacity Market contract (the "CM Contract"). This means that Pyebridge will retain the current CM Contract's associated annual gross profit margin income of c. £308,000 which is paid and received monthly in arrears.
In addition to the current CM Contract, as previously announced MED's Pyebridge site has secured further Capacity Market contracts to ensure minimum annual gross profit margin income totaling c. £817,000 until 2028. The Pyebridge site's Capacity Market contracts' gross profit margin income payments are in addition to its electricity generation trading revenue via its PPA with Statkraft.
Further, following the recent successful completion of the first phase of the Pyebridge work programme, the final preparations for the next larger second phase (the "2nd Phase") are near complete, and implementation is expected shortly. The 2nd Phase will be performed in separate consecutive tranches on each of the Pyebridge site's 3x gensets, and is expected to take around 6 to 8 weeks per genset. The completion of each of the three consecutive tranches of the 2nd Phase will result in each of the 3x gensets operating and generating at its full expected availability, efficiency, revenue generation and profitability potential.
The MED management team is working closely with RiverFort regarding the implementation of the 2nd Phase which will be funded under the new Funding Agreement (see RNS dated 28 February 2024 for further details). MED appreciates the ongoing support that RiverFort provides to the Company and Pyebridge.
Pieter Krügel, director general de MED, comentó: "We are pleased that our Pyebridge asset has successfully passed its SPD requirements, resulting in the retention of its current CM Contract's associated annual gross profit margin income of c. £308,000. The next step in the process at Pyebridge is to kick off the 2nd Phase of the work programme, which is expected shortly. We are looking forward to updating the market with progress in due course."
EXTREMOS
Este anuncio contiene información privilegiada a efectos de la versión del Reino Unido del Reglamento sobre abuso de mercado (UE n.º 596/2014), ya que forma parte de la legislación nacional del Reino Unido en virtud de la Ley de la Unión Europea (Retiro) de 2018 ("UK MAR" ). Tras la publicación de este anuncio, esta información privilegiada ahora se considera de dominio público.
Para más información, visite www.med.energia o contacte:
Pieter Krugel | Energía del mástil Desarrollos PLC | CEO | |
jon belliss | 44 0 20 7399 9425 | Valores Novum | Sector empresarial Broker |
RNS puede usar su dirección IP para confirmar el cumplimiento de los términos y condiciones, para analizar cómo interactúa con la información contenida en esta comunicación y para compartir dicho análisis de forma anónima con otros como parte de nuestros servicios comerciales. Para obtener más información sobre cómo RNS y la Bolsa de Valores de Londres utilizan los datos personales que nos proporciona, consulte nuestra Política de privacidad.